Pazopanib in Patients With Progressive Recurrent and/or Metastatic Salivary Gland Carcinoma

Inclusion Criteria:

• Histologically confirmed diagnosis of recurrent and/or metastatic salivary glands (including ACC and non ACC).

• Progressive disease within 6 months before inclusion as assessed by CT and/or MRIusing at least two measurements (RECIST v1.0) with at least one measurable targetlesion >10 mm.

• Recurrent and/or metastatic salivary glands carcinoma failing locoregional therapy,without possibility of curative treatment.

• Patients may have had unlimited prior therapy but must have had at least 4 weeksbetween any chemotherapy, radiotherapy, surgery and study enrollment.

• Tumoral tissue must be provided for subsequent histological review and biomarkeranalysis.

• Euthyroid patient.

• Hepatic, renal, cardiac and hematology normal functions.

• Ability to take oral medication.

Exclusion Criteria:

• Non salivary gland carcinoma (lachrymal gland tumor is excluded).

• Known or symptomatic cerebral metastasis.

• Patients treated with strong inhibitor or inductor of CYP3A4 within 14 days beforeinclusion.

• Presence of uncontrolled infection.

• Diagnosis of any previous malignancy within the last 5 years, except for completelyresected non-melanomatous skin carcinoma or successfully treated in situ carcinoma.

• Stable disease.

• Corrected QT interval (QTc) >480 msecs using Bazett's formula.